Making AI Useful in Clinical Trials Without Losing Control of Quality
Ask ten clinical operations leaders about AI and you will hear ten different pilot stories. Some saved weeks on document preparation. Others spent months on a tool that never left the test environment. The difference usually has little to do with the technology itself.
How is AI used in clinical trials today?
AI is being applied across the trial lifecycle, though maturity varies by task. Common uses include:
-
Feasibility and site selection: analyzing historical performance and patient availability to shortlist sites
- Document drafting: producing first drafts of protocols, informed consent forms and study reports for human review
- Data review: flagging anomalies and inconsistencies for data managers to check
- Safety support: helping teams process and prioritize incoming safety information
- Participant engagement: tailoring reminders and communications
In each case, the strongest results come when AI supports a person who remains responsible for the decision.
What are the main risks?
The risks are practical, not theoretical. Poor-quality input data produces poor-quality output. Tools that cannot explain how they reached a result are hard to defend in an inspection. Sensitive participant data may be exposed if vendors handle it carelessly. And teams can place too much trust in a confident-sounding answer.
Four questions to ask before adopting any AI tool
- Where does the data come from? Know what the tool was trained on and what it will be given.
- How was it validated? Ask for evidence that it performs reliably for your specific use, not just in general.
- Who checks the output? Define the human review step and who is accountable.
-
How transparent is the vendor? You should be able to learn how the tool works, how it changes over time and how your data is protected.
If a vendor cannot answer these clearly, the tool is not ready for regulated work.
Governance comes before scale
Regulators expect sponsors to maintain control of quality and data integrity regardless of the tools used. A simple governance model helps: a named owner for each tool, a risk assessment before use, clear documentation of intended purpose, and periodic review once the tool is live. This need not be heavy. It does need to exist before the pilot grows into a standard process.
Why pilots stall
-
Pilots rarely fail because the algorithm is weak. They stall because:
The problem was not well defined at the start
- The tool does not fit into existing systems and workflows
- Operations staff were not involved in selection
- Nobody owns the path from pilot to routine use
-
Data security or compliance questions arrive late and halt progress
Teams that avoid these traps tend to start small, pick a task with a clear measure of success and involve the people who will use the tool daily.
Learning from peers at the Evolution Summit
Turning AI into trusted, practical tools while safeguarding quality, data security and compliance is the first key topic of the Evolution Summit, held 19 to 20 January 2027 at the Four Seasons Hotel Westlake Village.
The program draws on leaders working at the intersection of operations and technology. Terri Roberson, AVP, Clinical Operations and Tech Solutions at Eli Lilly, Jeff Cohen, Associate Director, Digital Health, Immunology at Johnson & Johnson, Ramya Palacholla, Director, Digital Science at Evinova (AstraZeneca), and John Rootenberg, Principal Director, Digital Safety and Decision Support at Genentech, are among the speakers. Their roles reflect the range of questions executives face, from workflow design to safety decision support.
The Summit combines executive case studies with peer benchmarking, so delegates can compare what has worked, what has stalled and what they would do differently. For senior leaders deciding where to invest next, that candid exchange is hard to find elsewhere.
Enquire Today - https://www.marcusevans.com/summit/evolution/jan27